Companies: 10,795·Total market cap: $144.5T
Altimmune, Inc.

Altimmune, Inc.

ALTNASDAQHealthcare● Active
$2.73
+$0.02(+0.71%)
Market Cap$240880649
P/E Ratio
52W High$7.73
52W Low$2.56

Altimmune, Inc. (ALT) Stock Forecast & Analyst Price Target

Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.

alt · stock forecast · 15 analysts (3M) · FMP · updated Jun 8, 2026

Analyst Rating & Consensus

Based on 15 Wall Street analysts in the past 3 months

SellBuy

Buy

15 analysts

consensus

Rating Breakdown

Strong Buy
0
Buy
12
Hold
3
Sell
0
Strong Sell
0
Total: 15 · Buy rate: 80.0%

12-Month Price Target

High

$20.00

Consensus

$11.25

+310.7% upside

Low

$2.50

Median: $11.25 · Last Close: $2.74

The Altimmune, Inc. (ALT) analyst consensus is Buy, based on ratings from 15 Wall Street analysts over the past 3 months. The average 12-month ALT price target is $11.25, representing +310.7% upside from the current price of $2.74.

12-Month Price Target Forecast

Historical closing prices + analyst 12-month price target forecast cone

Historical priceConsensus $11 (310.7%)

Consensus Target

$11.25

310.7% upside

High Target

$20

630.2%

Low Target

$2.5

-8.7%

Current Price

$2.74

as of today

Based on analyst price targets, the ALT stock price prediction for the next 12 months ranges from $2.5 to $20. The consensus ALT price forecast of $11.25 implies 310.7% upside from the current price of $2.74.

Short-Term Price Prediction

Bear

Algorithmically generated · Updated daily

DatePredicted PriceChange
2026-06-09$2.672.61%

1-day model range: $2.64–$2.69. Peak: $2.69 (-2.61%).

Long-Term Stock Price Prediction

⚠️ Long-term projections are hidden until 252 trading days of history (IPO / limited listing). Short-term tab may still show model output.

Stock Forecast Based on Technical Analysis

14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency

Market Sentiment

BEARISH

Based on 14 technical indicators

0%7%93%
0Buy
1Neutral
13Sell
RSI (14)46.8Neutral
MACDBEARISH

Refreshes daily from EOD close

Moving Averages · ALT · Jun 8, 2026

Simple Moving Average (SMA)
MA 5$2.83SELL
MA 10$2.92SELL
MA 20$2.92SELL
MA 50$3.05SELL
MA 100$3.71SELL
MA 200$3.93SELL
Current $ALT · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$2.82SELL
EMA 10$2.87SELL
EMA 20$2.92SELL
EMA 50$3.13SELL
EMA 100$3.45SELL
EMA 200$3.75SELL
Current $ALT · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

Latest Analyst Ratings & Upgrades

Filter:
HC Wainwright & Co.2026-05-18
Maintains
BuyBuy
Citizens2026-05-14
Maintains
Market OutperformMarket Outperform
HC Wainwright & Co.2026-03-16
Maintains
BuyBuy
B. Riley Securities2026-03-06
Maintains
BuyBuy
Citizens2025-11-07
Maintains
Market OutperformMarket Outperform
HC Wainwright & Co.2025-10-20
Maintains
BuyBuy
HC Wainwright & Co.2025-10-10
Maintains
BuyBuy
HC Wainwright & Co.2025-08-13
Maintains
BuyBuy
UBS2025-08-13
Maintains
BuyBuy
B. Riley Securities2025-08-13
Maintains
BuyBuy

Wall Street analysts have recently issued updated ratings on Altimmune, Inc. (ALT) stock. Of the recent 64 rating actions, 0 were upgrades and 3 were downgrades. 15 analysts currently cover ALT.

Analyst Recommendation Trends

Buy ratings12↑ +1
Hold ratings00
Sell ratings00

ALT analyst recommendation trends show increasing buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 2 per month.

Financial Forecast: EPS & Revenue Estimates

Revenue This Year

$0M

↓ 100.0% YoY

Revenue Next Year

$26M

↑ 501964.4% YoY

EPS This Year

$-0.69

EPS Next Year

$-0.76

↑ 11.0% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast ALT EPS of $-0.69 for the current fiscal year, based on estimates from 6 analysts. The ALT revenue forecast is $0M for the current year. These are analyst consensus estimates via FMP / S&P Global.

About Forecast & Price Prediction

The ALT stock forecast is supported by two independent data sources: analyst consensus ratings from 15 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus ALT price target is $11.25 (+310.7% upside), with an analyst consensus of Buy.

The ALT short-term stock prediction for tomorrow is $2.67 (-2.61%).

Altimmune, Inc. trades on NASDAQ under the ticker ALT. The ALT stock outlook for 2027 is broadly positive, supported by a Buy consensus among 80% of covering analysts.

FAQ answers synthesize analyst targets, estimates, and on-page model outputs where shown.

Frequently asked questions

ALT forecast · 8 questions

According to 15 Wall Street analysts, the average 12-month ALT price target is $11.25, with a high forecast of $20.00 and a low of $2.50. The median price target is shown in the chart above when available. This implies +310.7% potential upside from the current price of $2.74.

ALT price targetWhat is ALT price targetALT analyst price targetALT 12-month target

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.